{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:55:09Z","timestamp":1788904509648,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.lungcan.2019.11.014","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T02:54:45Z","timestamp":1574218485000},"page":"8-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan"],"prefix":"10.1016","volume":"140","author":[{"given":"Ryo","family":"Morita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Okishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Hataji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yomota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-3317","authenticated-orcid":false,"given":"Osamu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Kibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-3000","authenticated-orcid":false,"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3557-0049","authenticated-orcid":false,"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8432-8975","authenticated-orcid":false,"given":"Toshiyuki","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Haku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-6096","authenticated-orcid":false,"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Hoshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.11.014_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/ITT.S125070","article-title":"Review of checkpoint immunotherapy for the management of non-small cell lung cancer","volume":"7","author":"Raju","year":"2018","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0010","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618801167","article-title":"Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety","volume":"12","author":"Hida","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199575","article-title":"Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: a systematic review and network meta-analysis","volume":"13","author":"Armoiry","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0030","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12885-019-5569-5","article-title":"Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis","volume":"19","author":"Vickers","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0040","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/cas.13225","article-title":"Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer","volume":"108","author":"Hida","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0045","article-title":"Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer","volume":"1","author":"Nishio","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0050","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdy041","article-title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","volume":"29","author":"Vokes","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0055","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1002\/cam4.2411","article-title":"Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of ONO-4538-05 and ONO-4538-06 studies","volume":"8","author":"Horinouchi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0060","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/JTO.0000000000000422","article-title":"EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey","volume":"10","author":"Yatabe","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203070","article-title":"Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: a retrospective study","volume":"13","author":"Yano","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0075","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1759-7714.13039","article-title":"Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and\/or after anti-PD-1 antibodies in lung cancer","volume":"10","author":"Uchida","year":"2019","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0080","series-title":"Pharmaceuticals and Medical Devices Safety Information","author":"Ministry of Health, Labour and Welfare","year":"2017"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","article-title":"Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study","volume":"119","author":"Fujimoto","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0090","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/1759-7714.12998","article-title":"Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients","volume":"10","author":"Shiono","year":"2019","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0095","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/1759-7714.13055","article-title":"Efficacy of subsequent docetaxel +\/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer","volume":"10","author":"Tamura","year":"2019","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.11.015","article-title":"Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data","volume":"126","author":"Dudnik","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0105","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","article-title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment","volume":"28","author":"Haratani","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-Mutated non-small cell lung Cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.11.014_bib0115","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2019.11.014_bib0120","article-title":"Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:33:14Z","timestamp":1759235594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219307287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"alternative-id":["S0169500219307287"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.11.014","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}